February 14, 2023
1 min watch
Save
VIDEO: Irinotecan liposome regimen promising in first-line metastatic pancreatic cancer
In a video interview with Healio, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, talked about the NAPOLI 3 trial data presented at ASCO Gastrointestinal Cancers Symposium.
The data showed that irinotecan liposome injection combined with 5-FU/leucovorin and oxaliplatin — a regimen also known as NALIRIFOX — prolonged OS and PFS compared with nab-paclitaxel and gemcitabine as initial treatment for patients with metastatic pancreatic ductal adenocarcinoma.
“It’s really nice to see this — makes things clearer as to what we should be giving in the first-line systemic setting in metastatic pancreatic cancer,” Monge said.
Reference:
- Wainberg ZA, et al. Abstract LBA661. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 19-21, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Monge is the recipient of the Winn Career Development Award.